Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer PatientsBenzinga • 06/07/21
Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual MeetingGlobeNewsWire • 06/07/21
Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual MeetingGlobeNewsWire • 06/07/21
Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual MeetingGlobeNewsWire • 05/24/21
Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 PatientsGlobeNewsWire • 05/19/21
Veru, Inc. (VERU) CEO Mitchell Steiner on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/12/21
Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription RevenuesGlobeNewsWire • 05/12/21
Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 05/05/21
Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer PatientsBenzinga • 05/05/21
Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021GlobeNewsWire • 05/05/21
Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer CongressGlobeNewsWire • 04/21/21
Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewsWire • 03/02/21